Xenon (XENE)
NASDAQ:XENE
XENE Stock Chart & Stats
$55.53
-$0.78(-1.91%)
At close: 4:00 PM EST
$55.53
-$0.78(-1.91%)
Day’s Range― - ―
52-Week Range$26.74 - $63.95
Previous CloseN/A
Volume41.45K
Average Volume (3M)1.80M
Market Cap
$5.20B
Enterprise Value$4.43B
Total Cash (Recent Filing)$548.89M
Total Debt (Recent Filing)$7.94M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
May 12, 2026EPS Estimate
-1.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding83,190,315
10 Day Avg. Volume2,246,647
30 Day Avg. Volume1,804,546
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)6.11
Price to Sales (P/S)473.62
P/FCF Ratio-12.69
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue590.45
Enterprise Value/Gross Profit-62.55
Enterprise Value/Ebitda-12.32
Forecast
1Y Price Target
$75.82Price Target Upside36.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)-4.83
Revenue Forecast (FY)$5.45M
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPhase 3 topline results reported a larger-than-expected reduction in seizures versus placebo and exceeded prior trial benchmarks, increasing confidence in meaningful clinical benefit for hard-to-treat patients.
Commercial Potential And ValuationAnalyst upgrades to sales and valuation estimates and management commentary about potential premium pricing reflect expectations for significant market penetration and meaningful upside to company value.
Dosing Convenience And TolerabilityOnce-daily dosing with no formal titration and minimal drug–drug interactions, combined with a favorable tolerability profile, supports easier use in routine practice and broader adoption beyond specialty centers.
Bears Say
Regulatory And Market-access RiskMaterial regulatory risk and the need for national drug scheduling create the possibility of delayed approval or restricted launch that would affect timing and availability of the medicine.
Safety/tolerability ConcernsSlightly increased reports of dizziness in trials could constrain uptake among certain patients, prompt label warnings, or necessitate dose adjustments that limit use in some populations.
Uncertainty In Depression IndicationA Phase II study in major depressive disorder failed to meet its primary endpoint, leaving the drug’s efficacy in depression unclear despite some supportive secondary signals and raising development risk for that indication.
Xenon News
XENE FAQ
What was Xenon’s price range in the past 12 months?
Xenon lowest stock price was $26.74 and its highest was $63.95 in the past 12 months.
What is Xenon’s market cap?
Xenon’s market cap is $5.20B.
When is Xenon’s upcoming earnings report date?
Xenon’s upcoming earnings report date is May 12, 2026 which is in 46 days.
How were Xenon’s earnings last quarter?
Xenon released its earnings results on Feb 26, 2026. The company reported -$1.31 earnings per share for the quarter, missing the consensus estimate of -$1.192 by -$0.118.
Is Xenon overvalued?
According to Wall Street analysts Xenon’s price is currently Undervalued.
Does Xenon pay dividends?
Xenon does not currently pay dividends.
What is Xenon’s EPS estimate?
Xenon’s EPS estimate is -1.18.
How many shares outstanding does Xenon have?
Xenon has 83,190,315 shares outstanding.
What happened to Xenon’s price movement after its last earnings report?
Xenon reported an EPS of -$1.31 in its last earnings report, missing expectations of -$1.192. Following the earnings report the stock price went down -3.762%.
Which hedge fund is a major shareholder of Xenon?
Currently, no hedge funds are holding shares in XENE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xenon Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$75.82 (36.54% Upside)
$75.82 (36.54% Upside)
Blogger Sentiment
Bullish
XENE Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 603.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 38.1%
Last 30 Days ▲ 38.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
59.22%
12-Months-Change
Fundamentals
Return on Equity
-55.81%
Trailing 12-Months
Asset Growth
-8.00%
Trailing 12-Months
Company Description
Xenon
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
XENE Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in Xenon's late-stage and early-stage clinical programs, particularly for azetukalner in epilepsy and neuropsychiatric disorders. Financially, the company is well-positioned to support its operations and pipeline development. While challenges exist, such as increased competition and screening hurdles, the positive advancements and robust financial health contribute to an overall optimistic outlook.View all XENE earnings summariesXENE Stock 12 Month Forecast
Average Price Target
$75.82
▲(36.54% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Viking Therapeutics
―
Scholar Rock Holding
―
Immunovant
―
Mineralys Therapeutics, Inc.
―
Ownership Overview
0.13% Insiders
31.00% Mutual Funds
48.28% Other Institutional Investors
14.90% Public Companies and
Individual Investors